TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03299166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule once daily (QD)
Study: NCT02337543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02305199
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
Study: NCT02305199
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid containing Sodium chloride 9 g/L
Study: NCT04272086
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml
Study: NCT02567331
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
Study: NCT00670254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application is identical to experimental arm
Study: NCT00670254
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
Study: NCT02254135
Drug: BEA 2180 BR - rising dose
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03510546
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study dose as per protocol.
Study: NCT04469907
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of AZD9977 under fasted conditions.
Study: NCT02739906
Drug: Regular human insulin (Huminsulin® Normal)
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
Study: NCT06243679
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with PD-1 inhibitors, up to 1 year.
Study: NCT04281862
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study: NCT04281862
Drug: Topical Prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care topical drop treatment
Study: NCT01341353
Drug: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648063
Drug: Femara® Tablets 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg, single dose fasting
Study: NCT01096355
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04681443
Drug: Crystallized phenol application
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystallized phenol application into the sinus tract
Study: NCT00887536
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
Study: NCT00887536
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles
Study: NCT01390376
Drug: DAAOI-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAOI-1 2g
Study: NCT01390376
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch pill
Study: NCT00508872
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Study: NCT00993382
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Study: NCT00411892
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT01841411
Drug: Metronidazole + N-Acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
Study: NCT01256424
Drug: HAL 5% with illumination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
Study: NCT01256424
Drug: HAL 1% with illumination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
Study: NCT01256424
Drug: HAL 0.2% with illumination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
Study: NCT01256424
Drug: Placebo ointment without illumination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a singe dose of 2g placebo ointment, no photoactivation
Study: NCT01907854
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin placebo tablets once-daily
Study: NCT02851277
Drug: ASP0892 Intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: NCT02851277
Drug: ASP0892 Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT02851277
Drug: Placebo Intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: NCT02851277
Drug: Placebo Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT00807911
Drug: Adjuvant FL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
Study: NCT00807911
Drug: Adjuvant FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
Study: NCT00821795
Drug: NPH/Regular 70/30 mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
Study: NCT04277897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Hepenofovir Fumarate Tablets
Study: NCT01151865
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
Study: NCT00004169
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00589823
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
Study: NCT00790595
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
Study: NCT00790595
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
Study: NCT00790595
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
Study: NCT00790595
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
Study: NCT00790595
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
Study: NCT04130633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vapor (distilled water)
Study: NCT01493791
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01253837
Drug: L19TNFa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles.
Study: NCT03219723
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (potency)
Study: NCT00525499
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle control applied topically twice daily for 12 weeks
Study: NCT03939429
Drug: QPX2015
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic
Study: NCT03939429
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01939236
Drug: Placebo (gummeline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days.
Study: NCT02425774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02796170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg pill taken once daily- placebo of Dapagliflozin
Study: NCT02213627
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01614886
Drug: ENA713
Approvals — FDA: no, EMA: no, PMDA: no
Description: -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
Study: NCT02213627
Drug: HP-hMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03149562
Drug: plasma transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: These critical ill neonates with plasma transfusions
Study: NCT03149562
Drug: non-plasma transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: These critical ill neonates without plasma transfusions
Study: NCT03755310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent dosage, route of administration and dose regimen
Study: NCT01589185
Drug: KBSA301
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
Study: NCT00260533
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (matching to atomoxetine)
Study: NCT01589185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a single intravenous infusion
Study: NCT04493255
Drug: [14C]E7090
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]E7090, oral capsule.
Study: NCT01761877
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02266511
Drug: Flomax®, Norman II facility
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02266511
Drug: Flomax®, Nishine facility
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01356615
Drug: low molecular weight heparin (enoxaparin sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
Study: NCT02558296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet to match active comparator
Study: NCT02989597
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative pain medication
Study: NCT02989597
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative pain medication
Study: NCT01356615
Drug: standard unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
Study: NCT02868632
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-L1 human monoclonal antibody
Study: NCT03219372
Drug: Pravastatin Pill
Normalized name: pravastatin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: statin
Study: NCT03219372
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00686413
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral
Study: NCT00533117
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
Study: NCT01263197
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT01263197
Drug: placebo for LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02700906
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
Study: NCT02837770
Drug: Diclofenac Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
Study: NCT02837770
Drug: Pacebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacebo pill will be administered 4 hours before the IVI.
Study: NCT02837770
Drug: Oral Diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
Study: NCT01773044
Drug: Placebo (for alcalinized lidocaine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01211210
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Study: NCT01211210
Drug: fluorouracil, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Study: NCT01211210
Drug: fluorouracil, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
Study: NCT00752063
Drug: Sorafenib with Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
Study: NCT03818321
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
Study: NCT01403532
Drug: Traditional intervention for HH using HCG and FSH
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
Study: NCT01403532
Drug: Sequential intervention for HH using HCG and FSH
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
Study: NCT01403532
Drug: Sequential intervention for HH using HCG and FSH plus zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
Study: NCT00106704
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet once daily for 24 weeks
Study: NCT01463644
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
Study: NCT03183297
Drug: JMI-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMI-001, a combination product of naproxen and fexofenadine
Study: NCT03183297
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 220mg
Study: NCT03183297
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT01107054
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of non-matched placebo on Day 4.
Study: NCT01995838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Study: NCT03516630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drops
Study: NCT00403520
Drug: Experimental 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Donepezil Hydrochloride 10 mg orally for 12 months
Study: NCT00403520
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Matching placebo orally for 12 months
Study: NCT01848769
Drug: CHF1535 pMDI + AC Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four inhalations for a total dose of BDP/FF 200/24 mcg
Study: NCT01848769
Drug: BDP + AC Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four inhalations for a total dose of BDP 200 mcg
Study: NCT00571493
Drug: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells.
Study: NCT01249261
Drug: Placebo/Risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
Study: NCT01743222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
Study: NCT02512783
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Study: NCT01049360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
Study: NCT03114683
Drug: PD1
Normalized name: STATLOCK UNIVERSAL PLUS LG VUPD1214
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI308 200mg/3 weeks
Study: NCT01572129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to the chronic daily dose of 75 mg
Study: NCT04467684
Drug: CB-0406 100 mg
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04467684
Drug: CB-0406 200 mg
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04467684
Drug: CB-0406 400 mg
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04467684
Drug: CB-0406 800 mg
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04467684
Drug: CB-0406 1,000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04467684
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color and size matched placebo
Study: NCT00023660
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023660
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02473341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated.
Study: NCT03247140
Drug: JLP-1401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Study: NCT03247140
Drug: Telmisartan/Amlodipine, Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Study: NCT03158532
Drug: Placebo I
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Study: NCT03158532
Drug: Placebo II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.